Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A US Multi-Site Observational Study in Patients With Unresectable And Metastatic Melanoma: The OPTIMIzE Study

NCT02780089 is registered in ClinicalTrials.gov with Bristol-Myers Squibb as lead sponsor.

NCT NCT02780089
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT02780089 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A US Multi-Site Observational Study in Patients With Unresectable And Metastatic Melanoma: The OPTIMIzE Study
Lead sponsor
Bristol-Myers Squibb
Phase
Observational
Overall status
Completed
Start date
October 23, 2015
Completion date
September 8, 2020
Enrollment
408 (actual)
Sites
66

Conditions

As the registry lists them; a condition with its own page is linked.

melanoma